Alumis Inc.
ALMS
Clasificación en acciones
#10177
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Precio por acción
$6.32
Capitalización bursátil
$818.03M
Cambio (1 día)
-0.32%
Cambio (1 año)
178.41%
País
US
Comercio Alumis Inc. (ALMS)
Categoría
Healthcare
Ratio P/B de Alumis Inc. (ALMS)
Ratio P/B al October 2026 TTM: 0.49
Según los informes financieros más recientes y el precio de las acciones de Alumis Inc., el ratio P/B actual (TTM) es 0.49. Al final de 2023, el ratio P/B era 0.80.
Historial del ratio P/B de Alumis Inc. desde 2021 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.49 | -27.66% |
| 2024 | 0.68 | -14.79% |
| 2023 | 0.80 | -36.26% |
| 2022 | 1.25 | -114.32% |
| 2021 | -8.75 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | 1,170.79% |
US
|
|
| 13.2547 | 2,594.59% |
US
|
|
| 4.208 | 755.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 1,156.84% |
NL
|
